Send to

Choose Destination
Euro Surveill. 2017 Feb 16;22(7). pii: 30464. doi: 10.2807/1560-7917.ES.2017.22.7.30464.

Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

Author information

EpiConcept, Paris, France.
Both authors have contributed equally to the study and manuscript writing.
The members of I-MOVE/I-MOVE+ study team are listed at the end of the article.


We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65-79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).


ILI; SARI; immunisation; influenza; influenza like illness; severe acute respiratory infection; vaccine effectiveness; vaccines

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for European Centre for Disease Prevention and Control (ECDC) Icon for PubMed Central
Loading ...
Support Center